Anima Biotech

Description

• Anima Biotech is pioneering Translation Control Therapeutics, a new class of drugs that control protein translation. Our novel drug discovery platform enables for the first time the visualization and control of protein synthesis by ribosomes. This opens a new way to approach hard or undruggable targets by decreasing or increasing a target proteins production. We are seeing an overwhelming interest from Pharma partners in multiple therapeutic areas. Our pipeline is currently in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (RSV interfering with viral protein synthesis by host cellas ribosomes) and CNS (initially, Autism regulating protein synthesis in the synapses of the brains neurons) in all of these diseases protein translation is a key factor in the underlying biology. Our platform is nearly universal and we intend to quickly expand to additional areas on our own and through partnering with Pharma in their drug discovery programs. Please watch the movie about our vision and technology at https://youtu.be/XNIr6MqfSYEand the interview with Pharma Television channel: https://youtu.be/dFfwXAfSYp0Animas protein synthesis monitoring (PSM) technology was originally developed over 7 years in close collaboration with the ribosome biochemistry lab at Penn university. We have achieved strong technology validation with 5 granted patents, 2 pending patents, 17 scientific collaborations, 13 peer reviewed publications. So far we have raised $22m, including $10m in NIH research grants.
• 

  Headquarters:75 Claremont Road , Bernardsville, New Jersey, United States

  More
• 

  Phone Number:

• 

  Website: https://www.animabiotech.com

• 

  Employees:34

• 

  Revenue:$10 - 50M

• 

  Legal Name:Anima Biotech

• Anima Biotech's Social Media

  
• Is this data correct?

• |  NAICS Code: 541713  |

  Show More